Not yet a member?Join now!|Lost password
Agilent Technologies Inc.
Agilent Technologies Inc.
12/07/2012 | Press release
Agilent Technologies Microarrays Used in Groundbreaking Prenatal Research Study Published in New England Journal of Medicine
distributed by noodls on 12/07/2012 14:14
Data Significantly Increases Understanding of Prenatal Abnormalities
SANTA CLARA, Calif., Dec. 7, 2012
Agilent Technologies Inc. (NYSE: A) today announced its microarrays were used in a landmark prenatal research study published on Thursday in the New England Journal of Medicine. The three-year collaborative study, "Chromosomal microarray versus karyotyping for prenatal diagnosis," represents a significant milestone in understanding prenatal abnormalities. Agilent SurePrint CGH microarrays were used for the majority of the 4,400 cohort samples. Use of this technology enabled researchers to detect smaller aberrations compared to traditional karyotyping.
Researchers from Emory University, Baylor College of Medicine, Columbia University and Signature Genomics collaborated in this study. Their primary objective was to evaluate the accuracy, efficacy and potential advantages of using microarray analysis compared with conventional karyotyping. Their secondary objective was to evaluate analytical performance. The study was sponsored by the National Institute of Child Health and Human Development.
Agilent was the primary contributor of microarrays and reagents used in this study; 71 percent of samples were run on Agilent SurePrint CGH microarrays. Agilent assisted investigators in developing customized arrays for the study.
"We are honored to have participated in this landmark study, furthering technology adoption for improved discovery," said Robert Schueren, vice president and general manager of Agilent's Genomics Solutions Division.
A total of 5,500 arrays were used. The majority of the samples were composed of uncultured amniotic fluid and chorionic villi. All samples were also sent to a reference lab for chromosome analysis. All data was submitted to the National Center for Biotechnology Information and is available to the public free of charge.
Agilent's custom microarrays are manufactured to customer-specified designs. They are not approved or cleared by the U.S. Food and Drug Administration for use in diagnostic procedures. Customers are responsible for FDA approval/clearance prior to diagnostic use.
About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012.www.agilent.com.
# # #
Contact:
Susan Berg
+1 408 553 7093
susan_berg1@agilent.com
